Pharmaceuticals News

Partnership combines venture creation and biologics discovery to accelerate novel medicines through human clinical proof of conceptFirst-of-its-kind collaboration between a specialist biotech venture...

•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD, May ...

SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to...

Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc....

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial)  Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01...

Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01)  Analyse intermédiaire de phase 2 pivot attendue en Q4 2026Dépôt de demande d'autorisation de mise sur le...

In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled Agreement signed in May with leading...

Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase...

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to...